Publication:
Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience

Simple item page
dc.contributor.authorsOlgun, N.; Cecen, R. E.; Ince, D.; Onal, A.; Baysal, B.; Akyol, S.; Ozdogan, O.; Guleryuz, H.; Aktas, S.; Ozer, E.
dc.date.accessioned2022-03-10T18:02:08Z
dc.date.accessioned2026-01-11T08:00:57Z
dc.date.available2022-03-10T18:02:08Z
dc.date.issued2021
dc.identifier.doidoiWOS:000708132100434
dc.identifier.eissn1545-5017
dc.identifier.issn1545-5009
dc.identifier.urihttps://hdl.handle.net/11424/222396
dc.identifier.wosWOS:000708132100434
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofPEDIATRIC BLOOD & CANCER
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleDinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.endPageS215
oaire.citation.startPageS215
oaire.citation.titlePEDIATRIC BLOOD & CANCER
oaire.citation.volume68

Files

Collections

Araştırma Çıktıları